Q-omics provides the consensus-scored PLEKHO1 profile across patient tissues and cancer cell-line models. PLEKHO1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLEKHO1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PLEKHO1 protein abundance shows 22,362 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PLEKHO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHO1 survival associations across molecular data types. PLEKHO1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHO1 RNA expression–survival associations across cancer types. High PLEKHO1 expression shows unfavorable associations in KIRC, UVM and LGG, but favorable associations in SKCM, CESC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLEKHO1 RNA expression.
This table summarizes PLEKHO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHO1 shows lower tumor expression in BLCA, COAD and KICH and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher PLEKHO1 RNA expression in tumor versus normal tissue (log2 FC = +1.923, t-test p < 0.001).
This table shows molecular features associated with PLEKHO1 in patient tissues and cancer cell lines. In patient samples, PLEKHO1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
